Distribution of Streptococcus pneumoniae serotypes that cause parapneumonic empyema
Thoracoscopic decortication as first-line therapy for paediatric parapneumonic empyema
Impact of the pneumococcal conjugate vaccine on pneumococcal parapneumonic empyema.
Molecular typing of pneumococci causing parapneumonic empyema in Spanish children using multilocus sequence typing directly on pleural fluid samples.
1,2) Pediatric parapneumonic empyema
(PPE), a rare complication of bacterial pneumonia in children, has been increasing globally due to nonvaccine serotype replacements of S pneumoniae, with serotype 19A most commonly discovered.
Also, pneumococcal parapneumonic empyema
represented only 17% of the cases of identified invasive pneumococcal disease seen at that center in the years prior to the vaccine, but 32% of the cases after the vaccine (Pediatr.
We hypothesize that deaths caused by parapneumonic empyema
are increasing in Utah once again despite advances in critical care and the availability of antimicrobial drugs and new vaccines.
SAN FRANCISCO -- The incidence of pediatric pneumococcal parapneumonic empyema
doubled in Utah and surrounding areas since introduction of the pneumococcal conjugate vaccine, Carrie L.
In the past decade, Utah has had one of the highest rates of pneumococcal parapneumonic empyema
(PPE) in children due to Streptococcus pneumoniae serotype 1, which the vaccine does not cover, said Dr.
Pediatric parapneumonic empyema
(PPE) has been increasing in several countries including Spain.
16 cases per 100,000 children, respectively), the incidence of parapneumonic empyema
Early aggressive surgical management of parapneumonic empyemas